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Some evidence shows that fetal development may be a critical for the development of 
allergies and asthma later in life, and that DHA may play a key role in the development of the 
immune system. This study aimed to investigate the effects of DHA supplementation during this 
time period on the incidence of allergies and asthma up to six years of age. Women in the 
KUDOS cohort were given 600 mg of DHA or a placebo during their second and third trimesters 
of pregnancy, and their offspring were followed up to six years of age. Two-hundred thirty 
infants were included. Their medical records were collected until six years of age or until their 
records could no longer be acquired if the infant dropped out before six years of age. All records 
were coded and allergic diagnoses were examined for this study. These diagnoses were grouped 
into three categories, skin allergies, wheeze/asthma, and other allergies. Associations and relative 
risks were calculated for each type of allergy diagnosis and no significant associations were 
found. DHA supplementation during the prenatal period did not provide protection against 
asthma or allergies during the first year of life, the second through sixth years of life, or from 
birth to six years of age for any allergy, skin allergies, other allergies, or wheeze/asthma.  
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Chapter 1  
INTRODUCTION 
 In the past two decades, evidence has emerged that shows omega-3 polyunsaturated fatty 
acids (n-3 PUFAs) may protect against childhood asthma and allergies. Studies have been 
conducted using both prenatal and postnatal supplementation of marine n-3 PUFAs. Some of 
these studies supplemented during infancy, but this may not be the ideal time frame for allergy 
and asthma prevention. The prenatal period may be more critical, as discussed later in the review 
of literature. The cohort of the Kansas University DHA Outcomes Study (KUDOS) at the 
University of Kansas Medical Center was supplemented with an n-3 PUFA prenatally, making it 
a sample of convenience for studying childhood allergy and asthma development.  
Research on the use of prenatal and postnatal n-3 PUFA supplementation to prevent 
allergies and asthma has grown considerably in recent years, and this year a meta-analysis of 
randomized controlled trials was published (1). The analysis included trials of prenatal (five 
trials), postnatal (two trials), and both prenatal and postnatal supplementation (one trial). The 
analysis concluded there was a significantly reduced likelihood of any IgE-mediated allergy or 
eczema from one to three years of age, but not beyond this age. There was no significant effect 
on wheezing or asthma development. A major weakness acknowledged in the meta-analysis, 
however, was that only two of the studies had a low risk of bias. Thus, the results of the meta-
analysis could not be conclusive, and this warrants further investigation using sound methods 
with low risk of bias.  
Allergies and asthma are growing problems in the United States (2, 3). If these conditions 
are preventable with adequate n-3 PUFA consumption during pregnancy and infancy, this could 
be the focus of future dietary guidelines and primary prevention efforts in the United States. 
 2 
The purpose of the proposed research project is to explore the effect of prenatal DHA 
supplementation on development of childhood allergies and asthma.  
My research question is: Does prenatal supplementation with 600 mg of docosahexaenoic 
acid (DHA) compared to a placebo vegetable oil prevent the development of allergies or asthma 
in young children? 
My hypothesis is that prenatal DHA supplementation will reduce the development of 
both allergies and asthma in children.  
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Chapter 2 
REVIEW OF LITERATURE 
Childhood asthma and allergy prevalence 
Approximately 29.5 million Americans have asthma (2), including nearly one in ten 
children (2). Asthma is one of the most common diseases in childhood, and it accounts for 10.5 
million missed school days each year (4). Asthma prevalence has been increasing in the United 
states for over thirty years across all age, socioeconomic, and racial groups (2). Allergic 
conditions, which are related to asthma, are also increasing among children (3). 
Allergies are hypersensitivities that cause the immune system to react to things in the 
environment that should not provoke a reaction (3). Respiratory allergies are the most common 
type of allergies among children, affecting 17% of children in the United States in 2009-2011 
(3). In addition, 9.5 million American children have allergic skin conditions such as eczema (3). 
The prevalence of these is increasing. Approximately 12.5% of children had skin allergies in the 
United States in 2009-2011, compared to 7.4% less than 15 years earlier (3).  Food allergies are 
the third most common allergies in childhood, affecting around 5% of children in 2009-2011 (3). 
Respiratory allergies are the only type that did not increase from 1997-1999 to 2009-2011. The 
increases in allergies and asthma among children are alarming because both have potentially 
dangerous consequences.  
Consequences of childhood asthma and allergies 
One of the most dangerous consequences of allergies is anaphylaxis, a severe whole-body 
reaction that occurs rapidly and can be deadly (3). Severe respiratory distress occurs in 60-70% 
of children with anaphylaxis (5). Food allergies are the most common triggers for anaphylaxis 
(3). Asthma can also have dangerous consequences, and it is the third leading reason for 
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hospitalization of children (2). Asthma is highly hereditary (4), but researchers have discovered 
many environmental predictors of asthma and allergy development (6) which may explain their 
increasing prevalence. 
Importance of the prenatal and postnatal periods in development of asthma and allergies 
Some researchers believe that asthma and allergy development may be triggered in the 
intrauterine environment (6). One reason for this is that early life is the critical period for the 
establishment of the delicate balance of Th1 and Th2 cells required for proper immune function 
(6). Intrauterine factors associated with asthma or allergy development include preterm delivery, 
antibiotic use during pregnancy, inappropriate vitamin A intake during pregnancy (6), maternal 
smoking during pregnancy (7), and maternal asthma or allergies (8-10). In addition to these 
factors that may increase the risk of asthma and allergies, there are dietary factors during 
pregnancy and infancy that may decrease the risk of these conditions.  
Protective dietary factors during pregnancy and infancy 
Several nutritional factors during pregnancy and infancy may protect against childhood 
development of allergies and asthma. Erkkola et al. (11) found an inverse association between 
intake of vitamin D from food during pregnancy and asthma in offspring. Some studies have 
found that breastfeeding may protect against offspring asthma, eczema, and allergic rhinitis, but 
not food allergies (12). A case-control study showed that maternal intake of apples during 
pregnancy may be inversely associated with asthma development (13). Fish intake during 
pregnancy is another dietary factor that may have an inverse association with asthma and 
allergies. 
Epidemiological studies of fish intake in pregnancy and development of asthma or allergies  
Epidemiological studies of asthma 
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Several epidemiological studies have found that intake of oily fish during pregnancy may 
be inversely associated with the development of asthma and various allergic conditions (13-18). 
Oily fish is rich in omega-3 polyunsaturated fatty acids (n-3 PUFAs). Pike et al. (15) and Romieu 
et al. (15, 18) found an inverse association between plasma levels of n-3 PUFAs during 
pregnancy and offspring wheeze. Salam et al. (16) found an inverse association between 
maternal intake of oily fish during pregnancy and asthma in offspring, but this association was 
only found in offspring of asthmatic mothers.  
Epidemiological studies of allergies 
One epidemiological study showed an inverse association between fish intake during 
pregnancy and positive skin prick results for food allergens, but only in offspring of non-allergic 
mothers (14).  Three studies showed an inverse association between fish intake during pregnancy 
and offspring eczema (13, 17, 18). Only one cohort showed no association between maternal 
serum levels of omega-3 fatty acids during pregnancy, which are markers of fish intake, and 
allergy or asthma development in offspring (19). Most observational studies show an inverse 
association between fish intake during pregnancy, indicative of n-3 PUFA intake, and 
development of asthma and allergies in offspring.  
DHA in early development 
Alpha-linolenic acid is the main n-3 PUFA consumed from food, and it can be converted 
to eicosapentaenoic acid (EPA), which can then be converted to docosahexaenoic acid (DHA) 
(20). EPA and DHA are longer and more complex n-3 PUFAs than a-linolenic acid, and they 
are easier for the body to use. Preformed EPA and DHA can also be consumed from food. One 
of the main n-3 PUFAs under exploration is DHA. DHA is essential throughout the lifespan, and 
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it may be especially important during the third trimester of pregnancy and the first several 
months of after birth when infants organs are developing and growing rapidly (20).  
During pregnancy, adequate intake of DHA is essential for central nervous system 
development (20). DHA and arachidonic acid (AA) are the two most common long-chain PUFAs 
that comprise neural tissues (21), so DHA is critical for brain development. Fetal organs such as 
the liver and brain use large amounts of DHA as they grow (20), so it is important for women to 
consume adequate DHA during pregnancy.  
DHA sources and recommended intake 
Some fish are a food source with a high concentration of DHA per serving, particularly 
cold water fatty fish such as salmon, tuna, and sardines (20). Consensus recommendations state 
that women should consume at least 200-300 milligrams of DHA during pregnancy and lactation 
(21, 22). This can be met by consuming one or two servings of fatty fish per week (22). Nochera 
et al. found that most low-income women are not meeting this recommendation (23). In this 
study, United States citizens consumed only 2.45 g/month of EPA and DHA combined (23)—
well short of recommendations. Another study found that the median DHA intake of mothers in 
Mexico was 55 mg/day (24). This is not surprising given the change in intake of n-3 and n-6 
fatty acids over the past several decades (25).  
Intake of omega-3 and omega-6 fatty acids 
Over the last 20 to 30 years, intake of n-3 PUFAs has decreased, while intake of omega-6 
fatty acids (n-6 PUFAs) has increased (25).  This change in intake of PUFAs correlates with the 
increase of allergies and asthma, and researchers have proposed that this intake pattern may be 
responsible for the rise in allergies and asthma (26). Researchers have proposed a mechanism for 
the correlation between PUFA intake and development of asthma and allergies. 
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Proposed mechanism of PUFAs in allergy and asthma development  
Aggravating role of arachidonic acid 
Linoleic acid is the main n-6 PUFA consumed, and it is found in vegetable oils and other 
foods derived from them (27). Arachidonic acid (AA), an n-6 PUFA is readily synthesized from 
linoleic acid, is a precursor to mediators that play a role in the development of allergies and 
asthma (27). Eicosanoids are mediators that can be produced from AA, and one key eicosanoid 
in the development of allergies and asthma is prostaglandin E2 (PGE2) (27). PGE2 enhances 
production of immunoglobulin E (IgE), which encourages the development of allergies and 
asthma (26, 27). Thus, a high intake of n-6 PUFAs has been proposed to contribute to the 
development of these conditions (26, 27). Conversely, n-3 PUFAs may oppose the action of AA 
in this process.  
Protective role of omega-3 fatty acids, particularly EPA and DHA 
Long chain n-3 PUFAs (EPA and DHA) occupy the same space as AA in inflammatory 
cell membrane phospholipids, so increasing consumption of DHA and EPA reduces AA in these 
membranes (28). Since AA is needed to produce PGE2, this decreases the amount of PGE2 that 
can be produced (26). In addition, EPA and DHA in particular inhibit cyclo-oxygenase, an 
enzyme necessary for forming PGE2 from AA (26). Lower levels of PGE2 result in lower IgE 
levels and potentially lower chances of developing asthma or allergies (26). This finding laid the 
foundation for experimental research on the use of EPA and DHA for the prevention of allergies 
and asthma.  
Purpose of the review 
The discovery of a potential protective mechanism of DHA and EPA,and  the inverse 
associations between fish intake and asthma or allergies in epidemiological studies, led to 
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randomized controlled trials of DHA supplementation during pregnancy, lactation, and infancy 
designed to determine the effect of n-3 fatty acids on childhood asthma and allergies. These 
studies address the following question: does DHA supplementation reduce childhood 
development of allergies or asthma? The purpose of this review is to collate and interpret 
literature that is relevant to the hypothesis that DHA supplementation during pregnancy, 
lactation, and infancy reduces childhood development of asthma and allergies.  
Randomized controlled trials of DHA supplementation 
Prenatal supplementation 
Three studies were found that investigated the effects of prenatal DHA supplementation 
on asthma symptoms. Olsen et al. found a 63% lower hazard rate of asthma with marine n-3 
PUFA supplementation during the last trimester of pregnancy (6). The hazard rate of allergic 
asthma was reduced by 87%, a larger decrease than for total asthma. This study followed the 
offspring out to 16 years of age, the longest follow-up of all studies retrieved. Women in this 
study received 2.7 grams/day of EPA and DHA, with 1.2 g from DHA. Another study did not 
find a significant effect of supplementation on asthma symptoms in offspring of women with 
allergies who were given 400 mg/day of DHA from 18-22 weeks of gestation until delivery (24). 
A third study found no significant difference in wheeze at six months in offspring of women who 
received two portions of salmon per week from 20 weeks of gestation until delivery (29). 
Four studies of the effect of prenatal DHA supplementation on allergies were retrieved. 
Three of these studies showed protective effects (24, 25, 30). In these three studies, 
supplementation took place from ≤22 weeks of gestation through delivery. The level of DHA 
supplementation in these studies was 400 (24), 800 (24), and >2000 mg/day (25). 
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Dunstan et al. and Palmer et al. found that offspring of women who received 
supplementation had lower rates of sensitization to egg at 12 months of age (0.34 odds ratio, 0.11 
to 1.02 confidence interval (25); adjusted relative risk 0.62, 0.41 to 0.93 confidence interval (30), 
but only the second result was significant. Dunstan et al. found that severity, but not incidence, 
of atopic dermatitis (a form of eczema), was lower at one year of age in the intervention group 
(25). Palmer et al. (30) found that incidence of atopic eczema was lower (adjusted relative risk 
0.64, 0.40 to 1.02 confidence interval). A follow-up study at six years of age, however, showed 
no remaining protective effects against allergies (31). Escamilla-Nuñez et al. (24) found that 
offspring of atopic mothers in the intervention group were less likely to have nasal discharge, 
which may be associated with allergic rhinitis, at 18 months of age.  
Only one study retrieved for this review found no positive effect of n-3 fatty acids on 
allergies in the offspring.  In this study, pregnant women in the intervention group consumed two 
150-gram portions of salmon per week (29). Each portion contained 1.16 grams of DHA on 
average. This amounted to an average of 330 mg/day of DHA, lower than the amount in any of 
the three studies above. Women in the intervention group were given salmon from 20 weeks of 
gestation until delivery, and women in the control group were asked to continue consuming their 
usual diet. Follow-up occurred at six months of age, earlier than in the studies previously 
discussed. The results of this study were not clinically significant.  
Offspring of women in the intervention group did not have a lower incidence or 
decreased severity of atopic dermatitis compared to the control group at six months of age (29). 
Results of skin prick tests for common food and inhalant allergies did not significantly differ 
between groups, and neither were serum IgE levels. These results may have been influenced by 
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the comparatively low dose of DHA and the short follow-up period. The authors noted that a 
later follow-up period would be necessary to determine long-term clinical outcomes (29). 
Only one study of prenatal DHA supplementation and allergies continued 
supplementation during lactation (32, 33). Participants in this study had allergies or a family 
history of them. Women in the intervention group consumed capsules containing 1100 mg/day of 
DHA from 25 weeks of gestation through three to four months of breastfeeding. The control 
group received soybean oil capsules during the same period. The prevalence of both food allergy 
and atopic eczema was lower in the intervention group than the control group at one year of age 
(2% compared to 15%, p < 0.05; 8% compared to 24%, p < 0.05) (33). The incidence of all IgE-
related diseases in the intervention group was lower than in the control group at two years of age 
(13% compared to 30%, p = 0.01) (32), but a lower rate of allergy symptoms was not observed in 
the intervention group (32).  
Supplementation in infancy 
Studies of the effect of DHA supplementation in infancy were also retrieved. 
Three studies was retrieved that investigated DHA supplementation in infancy (34-36). In the 
first study, infants were supplemented with 500 mg/day of tuna oil (DHA amount not specified) 
(34). Parents were also given canola oil, rich in n-3 PUFAs, to use in cooking. The control group 
received placebo supplements and cooking oil rich in n-6 PUFAs. Follow-up was at eighteen 
months of age. The results showed that supplementation reduced the development of symptoms 
of asthma (34). The rate of asthma was not lower in the intervention group, but the occurrence of 
several symptoms and indicators of asthma severity were lower. These symptoms and indicators 
included wheezing, doctor visits for wheezing, and bronchodilator use.  The above study also 
investigated allergy occurrence (34). Results showed no effect of the intervention on allergy 
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development. The group with the highest plasma levels of n-3 PUFAs had insignificantly 
reduced IgE levels.  
 Foiles et al found that infant formula supplementation with varying levels of DHA 
(0.32%, 0.64%, and 0.92%) was protective against wheeze/asthma and allergies (35). Time to 
first diagnosis of allergic illness was delayed in the DHA supplemented groups. The effects of 
supplementation differed by whether maternal allergies were also present. In non-allergic 
mothers, DHA reduced the incidence of any allergy and skin allergies. If the mother reported 
allergies, DHA reduced the incidence of wheeze/asthma in the offspring. 
 Birch et al also conducted a study of DHA supplementation during infancy (36). In this 
study, exclusively formula-fed infants were given either formula supplemented with DHA and 
arachidonic acid (ARA) or a control formula without supplemental DHA or ARA for the first 
year of life. At three years of age, the children who had received the supplemented formula had 
significantly lower odds for developing wheezing/asthma (odds ratio (OR), 0.32; 95% CI, 0.11-
0.97) or any allergy (OR, 0.28; 95% CI, 0.10-0.72). These children also had lower odds for 
having an upper respiratory infection (OR, 0.22; 95% CI, 0.08-0.58). 
Conclusions 
Overall, most randomized controlled trials show a protective effect of maternal DHA 
supplementation on childhood development of allergies and asthma. Due to the relatively small 
number of studies and the discrepancies among them, more research is needed in this area to 
confirm the effects of pre- and post-natal DHA supplementation on childhood development of 
allergies and asthma. 
The studies used different forms of supplementation—from portions of salmon to fish oil 
capsules. The salmon study was useful for determining whether simply consuming the 
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commonly recommended amount of fatty fish is adequate to prevent allergies and asthma in 
offspring. Other studies used a variety of formulations of fish oil, containing different amounts of 
EPA and DHA. Research is needed to determine the optimal amount of DHA for allergy and 
asthma prevention. 
Only one study in this review investigated DHA supplementation during both the prenatal 
and postnatal period (32, 33), and this leaves room for further exploration of whether there are 
greater benefits from continuing supplementation after delivery. Early life seems to be a critical 
time period for allergy and asthma development, but research has not pinpointed when this 
crucial period ends. Thus, it may be beneficial to further investigate DHA supplementation 
during both pregnancy and lactation or infancy.  
The follow-up period in most of the studies was relatively short. Seven of the eight 
studies followed the offspring for two years or less. Olsen et al., the only study with a longer 
follow-up period, found that the hazard ratio for asthma were reduced at sixteen years of age in 
offspring of women who were given prenatal DHA supplementation (6). This finding should be 
investigated in more studies with a similar follow-up period. 
 Given the growing prevalence of childhood asthma and allergies, as well as the potential 
adverse outcomes and costs associated with these conditions, research on asthma and allergy 
prevention has the potential for significant impact. Widespread DHA supplementation during 
pregnancy and early life may help reverse the trend of rising allergy and asthma prevalence. This 
could save millions of dollars in healthcare costs per year in the United States alone. It could also 
improve quality of life for millions of children. Future research should determine the optimal 
dosage and period of DHA supplementation for asthma and allergy prevention and clarify long-





 The research project involved analyzing data previously collected from the KUDOS 
cohort at the University of Kansas Medical Center. This data included incidence of medically 
documented allergies, asthma, and associated symptoms of children in the cohort up to six years 
of age. This will allow the researcher to investigate the hypothesis that DHA supplementation 
during the second and third trimesters of pregnancy reduces childhood development of asthma 
and allergies. The following sections will provide details about the sample, setting, ethics, 
procedures, materials, analysis of data, and schedule of activities. 
Setting 
 All data collection took place at the University of Kansas Medical Center in Kansas City, 
Kansas. The data analysis for this research project will also take place at the University of 
Kansas Medical Center. 
Ethics 
 The Human Subjects Committee approved data collection for the KUDOS cohort. Data 
analysis for this project did not require further ethical review. 
Subjects 
 Women were enrolled in the study if they met the following inclusion criteria: 16.0-35.0 
years of age, 8-20 weeks of gestation (determined by ultrasound), agreed to consume study 
capsules until delivery, agreed to return to the study center for delivery, BMI less than 40, no 
serious illnesses (cancer, diabetes, lupus, hepatitis, sexually transmitted diseases, HIV), and 
availability by telephone. They were excluded for any of the following: < 16 or > 35 years of 
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age, BMI > 40, serious illness, expecting multiple infants, diabetes or gestational diabetes at 
baseline, elevated blood pressure, not planning to return to the study center for delivery, 
gestational age at baseline < 8 weeks or > 20 weeks, unable or unwilling to consume capsules 
until delivery, or unable to provide informed consent in English. 
 A total of 231 infants were included in the original cohort, whose mothers had consumed 
the capsules from a mean of 14 weeks of gestation until delivery. Of these, one participant was 
excluded from data analysis for this study due to a serious genetic disorder. For the survival 
analysis, subjects were grouped by the last year of life for which complete medical records had 
been obtained. All subjects were included for the rest of the analysis, regardless of whether their 
records were obtained up to six years of age. As seen in Figure 1, there were 231 participants 
whose mothers were enrolled in the original study. Of these, the mothers of 106 were assigned to 
the control group and the mothers of 125 were assigned to the DHA intervention. One subject in 
the DHA group was excluded from all analysis due to a genetic disorder. There were no 
significant differences between the baseline characteristics of the treatment and control groups, 
as shown in Table 1. Baseline data for certain risk factors, including paternal allergy, was 
missing for some subjects. 
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Table 1: Baseline characteristics of the study population 
Variable Control DHA P Value 
Male* 57 (53.8%) 59 (47.6%) 0.349 
Non-Black* 70 (67.3%) 89 (73.6%) 0.305 
Birthweight (grams)** 3302 ± 422 3417 ± 506 0.064 
Breastfed Days** 166 ± 208 181 ± 231 0.621 
Gestational Weight Gain (pounds)** 35.8 ± 15.6 39.0 ± 15.9 0.160 
Maternal Education (Years)** 14.0 ± 2.8  14.5 ± 2.8  0.136 
Maternal Allergies Ever Reported* 62 (62.6%) 66 (55.9%) 0.318 
Paternal Allergies Ever Reported* 42 (57.5%) 39 (47.6%) 0.215 
Yes to Maternal Ever Smoke* 49 (46.2%) 47 (37.9%) 0.202 
Yes to Furred Pets in the Home* 54 (54.0%) 58 (48.7%) 0.438 
Yes to Daycare Attendance by 12 Months 
of age* 
38 (48.7%) 41 (44.6%) 0.589 




 For the KUDOS cohort, women were randomized to either receive 600 mg total 
supplemental DHA in two capsules per day during the second and third trimesters of pregnancy 
or similar supplements with a mixture of corn and soybean oils. The DHA capsules contained a 
marine algal source of the nutrient (DHASCO, Martek Biosciences, Columbia, MD). The 
soybean oil capsules contained 120 mg of alpha-linolenic acid (ALA), a precursor of DHA. This 
amount of ALA is about 10% of the average amount consumed by US adults. Maternal levels of 
DHA were measured by collecting and analyzing blood drawn at baseline and delivery. All 
medical records from primary and specialty providers were collected and used as the records for 
incidence of allergies and asthma. Only medical diagnoses were coded and included in the 
analysis. 
 The following diagnoses were included in the analysis of wheeze/asthma (WA): 
wheezing, asthma, reactive airway disease, and allergic cough. Atopic dermatitis, eczema, and 
contact dermatitis were coded as skin allergies (SA). The following diagnoses were coded as 
other allergies (OA): allergic rhinitis, allergic sinusitis, allergic conjunctivitis, food allergy, drug 
allergy, allergic rhino-conjunctivitis, vaccine allergy, insect bite allergy, non-specified allergy, 
and anaphylaxis. All of the above diagnoses were included in the analysis for any allergy (AA).  
The researcher or another member of the research team received faxed copies of all 
medical records for study participants through six years of age.  Medical diagnoses in these 
records were then coded as one of four types of adverse events based on standard coding criteria. 
These types included infectious, allergic, unknown, and not applicable. Diagnoses were coded as 
allergies if the diagnosis included “allergy” or an allergic etiology, there was an allergy 
medication prescribed by the physician at the time of service, or the diagnosis was an evidence-
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based allergic condition (asthma, eczema, atopic dermatitis, reactive airway disease (RAD), and 
wheezing). All diagnoses were recorded in the KUDOS cohort ACCESS database.  
Materials 
 The intervention group was provided with capsules containing 600 mg per two capsules 
of DHA from marine algal sources during the second and third trimesters of pregnancy. The 
control group received capsules that were identical but contained a 50-50 mixture of corn and 
soybean oils and no DHA, as described above. All capsules were donated by DSM (formerly 
Martek Biosciences), Columbia, MD. For the proposed research project, the only material 
acquired was SAS University Edition 9.4. 
Data Analysis 
 Paired equal variance t-tests and Chi-squared tests were used to analyze similarity of 
baseline characteristics of the control and intervention groups. Time to first illness was analyzed 
using Wilcoxon tests and Kaplan-Meier survival curves. Chi-squared tests were used to examine 
associations and relative risks of allergic illness across treatment groups. Z-tests comparing two 
population proportions were used to calculate differences in wheeze/asthma when both treatment 
group and maternal allergies were included in the analysis. Exploratory data analysis was 
conducted using Chi-squared tests and binary logistic regression for categorical and continuous 
variables, respectively. A p value < 0.05 was considered significant for all analyses. The student 
researcher used SAS University Edition version 9.4 for all analysis except z-test calculations, 
which were conducted using cell counts from Microsoft Excel and an online statistical calculator 
(http://www.socscistatistics.com/tests/ztest/). Only the student researcher, statistician, and 
principal investigator of the study (the thesis chairperson) were aware of the treatment group 
assigned to each subject. 
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Schedule of activities 
 Most data collection had occurred prior to the beginning of the study, and collection of 
adverse events data up to six years of age was completed in June 2016. The student investigator 
began statistical analysis in February 2016 and completed this analysis in June 2016. The student 
investigator submitted the final paper for review on June 28, 2016. Oral defense of the thesis 




Incidence of at least One Allergic Illness 
 No significant difference was found in the incidence of at least one allergic illness by six 
years of age between the treatment and control group (Table 2). There were also no significant 
differences found in the incidence of allergy either during the first year or the first to the 6th year 
of age (Tables 3-4). 
 
Table 2. Incidence of at least one allergy diagnosis by six years of age. 
Diagnosis Type Control (n = 106) DHA (n = 124) P Value 
Any Allergy 60 56.6% 75 60.5% 0.551 
Wheeze/Asthma 26 24.5% 23 18.6% 0.270 
Skin Allergy 37 34.9% 44 35.5% 0.927 
Other Allergy 42 39.6% 40 32.3% 0.245 
P values calculated using Chi-squared analysis. 
  
Table 3. Incidence of at least one allergy diagnosis in first year of life. 
Diagnosis Type Control (n = 106) DHA (n = 124) P Value 
Any Allergy 28 26.4% 39 31.5% 0.402 
Wheeze/Asthma 3 2.8% 5 4.0% 0.620 
Skin Allergy 21 19.8% 28 22.6% 0.609 
Other Allergy 9 8.5% 9 7.3% 0.729 
P values calculated using Chi-squared analysis. 
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Table 4. Incidence of at least one allergy diagnosis from 12 to 71.99 months of age. 
Diagnosis Type Control (n = 106) DHA (n = 124) P Value 
Any Allergy 54 50.9% 64 51.6% 0.919 
Wheeze/Asthma 26 24.5% 22 17.7% 0.207 
Skin Allergy 29 27.4% 31 25.0% 0.685 
Other Allergy 38 35.9% 36 29.0% 0.270 
P values calculated using Chi-squared analysis. 
Relative Risk of having at Least One Allergic Illness 
 No significant difference was found between the relative risk of allergic illness in the 
control versus treatment group for the first year of life, the first six years of life, or between 
twelve and 71.99 months, as shown in Tables 5-7. 
 
Table 5. RR (including 95% confidence interval) of at least one allergy diagnosis by six 
years of age compared to the DHA group. 
Diagnosis Type Relative Risk 95% Confidence Interval 
Any Allergy 0.94 0.75-1.17 
Wheeze/Asthma 1.32 0.80-2.17 
Skin Allergy 0.98 0.69-1.40 




Table 6. RR (including 95% confidence interval) of at least one allergy diagnosis in first 
year of life compared to the DHA group. 
Diagnosis Type Relative Risk 95% Confidence Interval 
Any Allergy 0.84 0.55-1.27 
Wheeze/Asthma 0.70 0.17-2.87 
Skin Allergy 0.88 0.53-1.45 
Other Allergy 1.17 0.48-2.84 
 
 
Table 7. RR (including 95% confidence interval) of at least one allergy diagnosis from 12 
to 71.99 months compared to the DHA group. 
Diagnosis Type Relative Risk 95% Confidence Interval 
Any Allergy 0.99  0.77-1.27 
Wheeze/Asthma 1.38 0.83-2.29 
Skin Allergy 1.09 0.70-1.69 




Incidence of Wheeze/Asthma Based on Treatment Group and Maternal Allergies 
 Of all allergy types, the rate of wheeze/asthma appeared to differ the most between 
treatment groups, so further analysis was conducted that included maternal allergies (Tables 8 
and 9). This was to determine whether there was a stronger protective effect in offspring of 
women who reported allergies. The protective effect did appear to be stronger, with a 6.2% 
decreased incidence of wheeze/asthma by six years of age in offspring of allergic mothers who 
received DHA, compared to a 3.5% decreased incidence in offspring of non-allergic mothers 
receiving DHA (Table 9). 
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Table 8. Wheeze/Asthma Diagnosis from 12-71.99 mo based on Tx Group + Maternal 
Allergy* 
Control + Yes to Maternal 
Allergy Ever 
DHA + Yes to Maternal 
Allergy Ever 
P-Value 
17 out of 62 27.4% 13 out of 66 19.7% 0.303 
Control + No to Maternal 
Allergy Ever 
DHA + No to Maternal Allergy 
Ever 
P-Value 
7 out of 37 18.9% 8 out of 52 15.4% 0.660 
P-value calculated using Z-test for two independent population proportions. 
*Missing maternal allergy data for 13 participants (not included in this analysis). 
 
Table 9. Wheeze/Asthma Diagnosis in first six years based on Tx Group + Maternal 
Allergy* 
Control + Yes to Maternal 
Allergy Ever 
DHA + Yes to Maternal 
Allergy Ever 
P-Value 
17 out of 62 27.4% 14 out of 66 21.2% 0.412 
Control + No to Maternal 
Allergy Ever 
DHA + No to Maternal Allergy 
Ever 
P-Value 
7 out of 37 18.9% 8 out of 52 15.4% 0.660 
P-value calculated using Z-test for two independent population proportions. 
*Missing maternal allergy data for 13 participants (not included in this analysis). 
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Chapter 5  
DISCUSSION 
The results of this study show that prenatal supplementation with 600 mg DHA during 
the second and third trimester does not provide protection against allergic illness in the first six 
years of life. The lack of effect was consistent across all periods examined: the first year of life, 
the second through sixth years of life, and from birth to six years of age. Previous studies have 
shown conflicting evidence of protection against both allergies and asthma. 
Exploratory data analysis showed several interesting findings, which may be areas for 
further research. Offspring of women who did not report having an allergic illness were less 
likely to have an allergic illness during the first six years of life, and the difference almost 
reached a significant level (RR: 0.78, CI: 0.61-1.00). Males were significantly more likely to 
have had a wheeze/asthma diagnosis in the first six years of life than females (RR: 1.69, CI: 
1.01-2.85). Children who were not black had a significantly lower risk of both wheeze/asthma 
and skin allergy in the first six years (wheeze asthma RR: 0.60, CI: 0.37-0.98; skin allergy RR: 
0.57, CI: 0.41-0.80). DHA supplementation did not seem to provide additional protection against 
allergies or asthma in children who were black, males, or offspring of women with reported 
allergies. 
A strength of the study was its double-blind, placebo-controlled design. Many of the 
subjects were still coming to the study center for progress visits at the time of this project, so 
there was continued contact with these participants. Another strength was that only medically 
documented diagnoses of allergies and asthma were included, so parent reports were excluded. 
This increased the likelihood that only true allergic illnesses were examined in the study. 
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A limitation of the study was incomplete data for certain variables that were being 
examined, including paternal allergy data. Another limitation was that visual and neural 
development were the primary outcomes being studied in the KUDOS cohort, not incidence of 
asthma and allergies. Since only medically documented incidence of allergies and asthma were 
included in the analysis, the research heavily relied on complete and thorough medical 
examination and documentation from a wide variety of doctors. It was difficult to obtain medical 
records for certain subjects, and others dropped out of the study before six years of age. 
Sometimes parents took their child to multiple clinics or hospitals, so records may not have been 
received from all locations of care. Thus, while every effort was made to ensure complete 
medical records data collection and coding, some allergic events may have been missed. 
The lack of a protective effect could be due to the timing of supplementation. A previous 
study at the University of Kansas Medical Center showed protective effects of DHA when 
supplemented in formula during infancy (35). Since that trial, most formula companies have 
added DHA to their products. The subjects in the current trial who were breast-fed for less than 
100 days (n= 114 (49.6%)) were presumably formula-fed during part of their infancy, thus 
receiving supplemental DHA regardless of treatment group. When human milk fed, all infants 
also received DHA. This exposure to DHA may have obscured the protective effects of 
supplemental DHA which had been shown in previous studies. 
Alternatively, it is also possible that the protective effect of DHA against asthma and 
allergies is a more immediate effect, compared to the developmental programming effect that 
was hypothesized in this study. Future studies could examine the effect of DHA intake 
throughout childhood on the incidence of allergies and asthma. 
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In conclusion, the results of this study do not support the hypothesis that prenatal 
supplementation with 600 mg of DHA during the second and third trimesters of pregnancy 
protects against allergies and asthma up to six years of age. This result was consistent for 
incidence of skin allergies, wheeze/asthma, other allergies, or any allergic diagnosis. The effects 








There is some evidence to support the theory that fetal development may be a critical for 
the development of allergies and asthma later in life. DHA may play a key role in the 
development of the immune system. This study aimed to investigate the effects of DHA 
supplementation during this time period on the incidence of allergies and asthma up to six years 
of age. 
Women in the KUDOS cohort were given 600 mg of DHA or a placebo during their 
second and third trimesters of pregnancy, and their offspring were followed up to six years of 
age. Two-hundred thirty infants were included for analysis. Their medical records were collected 
until six years of age or until their records could no longer be acquired if the infant dropped out 
before six years of age. All records were coded and allergic diagnoses were examined for this 
study. These diagnoses were grouped into three categories, skin allergies, wheeze/asthma, and 
other allergies. 
Associations and relative risks were calculated for each type of allergy diagnosis and no 
significant associations were found. DHA supplementation during the prenatal period did not 
show a protective effect against asthma or allergies during the first year of life, the second 
through sixth years of life, or from birth to six years of age for any allergy, skin allergies, other 
allergies, or wheeze/asthma. 
Limitations of the study included a different primary outcome for the KUDOS cohort and issues 
inherent in using medical records. Strengths included the randomized, double-blind, placebo-
controlled design and medically documented-allergic illnesses. Further research could investigate 
continued DHA intake during childhood on the incidence of allergies and asthma.
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